CALLISTO PHARMACEUTICALS GRANTED ORPHAN DRUG DESIGNATION FOR ANNAMYCIN TO TREAT ACUTE LYMPHOBLASTIC LEUKEMIA

Callisto has announced that the Office of Orphan Products Development of the FDA has granted orphan drug designation to the company's drug candidate Annamycin for the treatment of acute lymphoblastic leukemia.

Annamycin, a second-generation anthracycline developed at M.D. Anderson Cancer Center, is being developed by Callisto to treat relapsed acute leukemia patients.

Callisto plans to begin a clinical trial in adult relapsed acute lymphoblastic leukemia patients in the near future.